Industries
| REVENUES | PROFITS | |||||
|---|---|---|---|---|---|---|
| Rank | Company | Global 500 rank | $ millions | % change from 2007 | $ millions | % change from 2007 |
| 1 | Johnson & Johnson | 103 | 63,747 | 4.3 | 12,949 | 22.4 |
| 2 | Pfizer | 152 | 48,296 | -0.3 | 8,104 | -0.5 |
| 3 | GlaxoSmithKline | 168 | 44,654 | -1.7 | 8,439 | -19.1 |
| 4 | Roche Group | 171 | 44,268 | 9.8 | 8,288 | 1.9 |
| 5 | Sanofi-Aventis | 181 | 42,179 | 5.5 | 5,637 | -21.8 |
| 6 | Novartis | 183 | 41,459 | 4.2 | 8,195 | -31.4 |
| 7 | AstraZeneca | 268 | 31,601 | 6.9 | 6,101 | 9.0 |
| 8 | Abbott Laboratories | 294 | 29,528 | 13.9 | 4,881 | 35.3 |
| 9 | Merck | 378 | 23,850 | -1.4 | 7,808 | 138.4 |
| 10 | Wyeth | 401 | 22,834 | 1.9 | 4,418 | -4.3 |
| 11 | Bristol-Myers Squibb | 435 | 21,366 | 7.0 | 5,247 | 142.4 |
| 12 | Eli Lilly | 455 | 20,378 | 9.4 | -2,072 | -170.2 |
| Rank | Company | Revenues % | Assets % |
|---|---|---|---|
| 1 | Johnson & Johnson | 20.3 | 15.2 |
| 2 | Pfizer | 16.8 | 7.3 |
| 3 | GlaxoSmithKline | 18.9 | 14.9 |
| 4 | Roche Group | 18.7 | 11.6 |
| 5 | Sanofi-Aventis | 13.4 | 5.6 |
| 6 | Novartis | 19.8 | 10.5 |
| 7 | AstraZeneca | 19.3 | 13.0 |
| 8 | Abbott Laboratories | 16.5 | 11.5 |
| 9 | Merck | 32.7 | 16.5 |
| 10 | Wyeth | 19.3 | 10.0 |
| 11 | Bristol-Myers Squibb | 24.6 | 17.8 |
| 12 | Eli Lilly | -10.2 | -7.1 |
From the July 20, 2009 issue
